Management of Snake Bite-Induced Pulmonary Embolism
Treat snake bite-induced pulmonary embolism with immediate anticoagulation using unfractionated heparin (UFH) with weight-adjusted bolus, NOT prophylactic anticoagulants, and prioritize snake-specific antivenom administration as the definitive therapy to neutralize procoagulant venom components—standard anticoagulation alone has proven ineffective in preventing thrombotic complications from snake venom.
Critical Context: Snake Venom Creates Unique Coagulopathy
Snake bite-induced PE represents a distinct clinical entity from standard venous thromboembolism. Viper venom (particularly Bothrops species) contains thrombin-like enzymes that create paradoxical thrombosis despite concurrent coagulopathy 1. Prophylactic anticoagulation fails to prevent thrombotic complications in this setting—a critical study of 50 snake bite patients showed 11 developed serious thromboses (including PE, cerebral infarction, myocardial infarction) at 36±27 hours post-bite despite early preventive anticoagulant therapy 1.
Risk Stratification: Apply Standard PE Categories
Once PE develops, stratify by hemodynamic status using the 2019 ESC framework 2:
High-Risk PE (Hemodynamically Unstable)
- Systolic BP <90 mmHg or requiring vasopressors
- Persistent hypotension
- Cardiac arrest
Intermediate-Risk PE
- Hemodynamically stable but with RV dysfunction on echo or elevated cardiac biomarkers
Low-Risk PE
- Hemodynamically stable without RV dysfunction
Acute Management Algorithm
Step 1: Immediate Anticoagulation
Initiate UFH with weight-adjusted bolus immediately upon PE diagnosis 2. For snake bite-induced PE specifically, UFH is preferred over LMWH because:
- Allows rapid reversal if bleeding complications develop
- Easier to titrate in the setting of venom-induced coagulopathy
- Can be temporarily held for antivenom administration if needed
Do NOT rely on anticoagulation alone—this is the critical pitfall. Standard anticoagulation does not neutralize the procoagulant venom enzymes driving ongoing thrombosis 1.
Step 2: Snake-Specific Antivenom (The Definitive Therapy)
Administer monospecific antivenom as soon as possible, ideally within 48 hours of the bite 1. In the study of 50 patients:
- 30 patients received antivenom (2-6 vials IV): all survivors recovered without permanent disability
- 16 patients NOT treated with antivenom: 6 developed systemic thrombosis with permanent disability in 3 cases
- 3 deaths occurred in patients who developed cerebral infarction before antivenom could be given
Antivenom neutralizes the thrombin-like glycoproteins that produce unstable fibrin and drive thrombosis 3. This addresses the root cause rather than just the downstream effect.
Step 3: Risk-Stratified Reperfusion Therapy
For High-Risk PE:
Systemic thrombolysis is recommended (Class I, Level B) 2:
- Standard alteplase dosing: 100 mg over 2 hours
- Critical consideration: Assess bleeding risk from snake bite site—local tissue damage may increase hemorrhagic complications
If thrombolysis contraindicated or fails 2:
- Surgical pulmonary embolectomy (Class I, Level C)
- Percutaneous catheter-directed treatment (Class IIa, Level C) 4
- Consider ECMO as bridge in refractory circulatory collapse (Class IIb, Level C)
For Intermediate-Risk PE:
Continue therapeutic anticoagulation with close monitoring 2. Rescue thrombolysis is indicated if hemodynamic deterioration occurs (Class I, Level B).
Do NOT routinely use primary thrombolysis in intermediate-risk PE (Class III, Level B) 2.
For Low-Risk PE:
Therapeutic anticoagulation alone is appropriate 2.
Step 4: Transition to Oral Anticoagulation
Once hemodynamically stable and venom effects neutralized:
- Prefer NOACs (apixaban, rivaroxaban, edoxaban, dabigatran) over VKAs (Class I, Level A) 2
- Exception: If severe renal impairment from snake bite complications, use VKA with INR target 2.0-3.0
Duration of Anticoagulation
Treat for minimum 3 months (Class I) 2. Snake bite represents a major transient/reversible risk factor, so:
- Discontinue anticoagulation after 3 months if this is the first PE episode (Class I) 2
- If recurrent VTE develops, continue indefinitely
Critical Pitfalls to Avoid
- Do NOT use prophylactic-dose anticoagulation—therapeutic dosing is required once PE develops
- Do NOT delay antivenom while waiting for anticoagulation to work—antivenom is the definitive therapy
- Do NOT routinely place IVC filters—only consider if absolute contraindication to anticoagulation (Class IIa, Level C) 2
- Do NOT assume standard anticoagulation will prevent progression—venom-induced thrombosis can continue despite adequate anticoagulation without antivenom 1
Monitoring and Follow-up
- Reassess at 3-6 months post-PE for persistent symptoms or chronic thromboembolic disease 2
- Monitor for late thrombotic complications—can occur up to 96 hours post-bite 1
- Evaluate for residual coagulopathy from venom effects
Special Considerations
Timing matters critically: Thrombotic complications typically develop 12-96 hours post-envenomation (mean 36 hours) 1. The therapeutic window for antivenom is narrow—all deaths in the landmark study occurred when cerebral infarction developed before antivenom administration 1.
Anaphylaxis risk with antivenom: 10% mild anaphylactic reactions, rare serum sickness responsive to steroids 1—this risk is acceptable given the alternative of permanent disability or death from thrombotic complications.